Inventor

Walter A. Blattler

Inventor

Brookline, MA, US

Overview

1985–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 45 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes22%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%

C07KPeptides17%

Y02ATechnologies for adaptation to climate change15%

C07DHeterocyclic compounds8%

G01NInvestigating or analysing materials by determining their chemical or physical properties5%

C12NMicroorganisms or enzymes5%

A01KAnimal husbandry2%

C07HSugars2%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%

PatentTitleYear

10,981,990Antibody molecules to TIM-3 and uses thereof2021 10,844,135Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said2020 10,752,687Antibody molecules to PD-1 and uses thereof2020 10,711,060Antibody molecules to LAG-3 and uses thereof2020 10,472,419Antibody molecules to TIM-3 and uses thereof2019 9,908,936'Antibody molecules to LAG-3 and uses thereof'2018 9,884,913'Antibody molecules to TIM-3 and uses thereof'2018 9,815,898'Antibody molecules to PD-1 and uses thereof'2017 9,683,048'Antibody molecules to PD-1 and uses thereof'2017 9,605,070'Antibody molecules to TIM-3 and uses thereof'2017 9,163,044'Carbon monoxide releasing molecules and uses thereof'2015 RE044704'Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents'2014 RE043899'Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents'2013 8,337,856'Methods of treatment using anti-ERBB antibody-maytansinoid conjugates'2012 8,198,417'Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates'2012 8,163,888'Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates'2012 8,093,358'Methods of treatment using anti-erbb antibody-maytansinoid conjugates'2012 8,088,387'Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates'2012 7,989,598'Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates'2011 7,585,857'Cytotoxic agents comprising taxanes and their therapeutic use'2009 7,575,748'Methods of treatment using anti-ErbB antibody-maytansinoid conjugates'2009 7,550,609'Cytotoxic agents comprising taxanes and their therapeutic use'2009 7,528,130'Cytotoxic agents comprising taxanes and their therapeutic use'2009 7,476,669'Cytotoxic agents comprising taxanes and their therapeutic use'2009 7,276,499'Cytotoxic agents comprising taxanes and their therapeutic use'2007 7,217,819'Cytotoxic agents comprising taxanes and their therapeutic use'2007 7,097,840'Methods of treatment using anti-ErbB antibody-maytansinoid conjugates'2006 7,008,942'Cytotoxic agents comprising taxanes and their therapeutic use'2006 6,706,708'Cytotoxic agents comprising taxanes and their therapeutic use'2004 6,630,579'Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use'2003 6,436,931'Cytotoxic agents comprising taxanes and their therapeutic use'2002 6,340,701'Cytotoxic agents comprising taxanes and their therapeutic use'2002 5,846,545'Targeted delivery of cyclopropylbenzindole-containing cytotoxic drugs'1998 5,585,499'Cyclopropylbenzindole-containing cytotoxic drugs'1996 5,475,092'Cell binding agent conjugates of analogues and derivatives of CC-1065'1995 5,416,064'Cytotoxic agents comprising maytansinoids and their therapeutic use'1995 5,395,924'Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity'1995 5,239,062'Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity'1993 5,208,020'Cytotoxic agents comprising maytansinoids and their therapeutic use'1993 4,888,415'Gelonin immunotoxin'1989 4,764,368'Acid-cleavable compound'1988 4,625,014'Cell-delivery agent'1986 4,618,492'Acid-cleavable compound'1986 4,569,789'Acid-cleavable compound, use in protein conjugates and drug delivery systems'1986 4,542,225'Acid-cleavable compound'1985

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1985–2021Patents assigned to DANA FARBER CANCER INST INC (14)· patent assignee history

1985–2021Based in Brookline, MA, US· patent location history

1993–2020Patents assigned to IMMUNOGEN INC (26)· patent assignee history

2012–2014Patents assigned to CHARI RAVI V J (6)· patent assignee history

2012–2014Patents assigned to BLAETTLER WALTER A (3)· patent assignee history

2017–2021Patents assigned to NOVARTIS AG (9)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
IMMUNOGEN INC	26	1993–2020
DANA FARBER CANCER INST INC	14	1985–2021
NOVARTIS AG	9	2017–2021
CHARI RAVI V J	6	2012–2014
BLAETTLER WALTER A	3	2012–2014

Locations

Location	Patents	Span
Brookline, Massachusetts, US	45	1985–2021